<p>
    Medications (Viral Prophylaxis):
</p>
<p>
    <strong>Valganciclovir / Ganciclovir</strong>
</p>
<ul>
    <li data-list-item-id="ec31229bb98c628ddbefd29cf37209f61">
         Indication for patients who are or received a CMV positive liver (i.e., D+/R- × 3 months, CMV D-/R+ or D+/R+ with ATG × 3 months)
    </li>
    <li data-list-item-id="ea531cb829f759d50951626c8de8ff0d8">
         Dose:
        <ul>
            <li class="ck-list-marker-bold" data-list-item-id="ec567d006ce4e05879d2aa99313e822ac">
                <strong> Valganciclovir: 900 mg PO daily (start 10–14 days post-LT).</strong>
            </li>
            <li data-list-item-id="ec9d909a897f1cc6c784ed812f00b41e8">
                 <strong>Ganciclovir</strong>: 5 mg/kg IV daily if absorption concerns.
            </li>
            <li data-list-item-id="eda6d1084b975ec9133dcc88807894107">
                 Renal-adjust per EGFR &nbsp;
            </li>
        </ul>
    </li>
</ul>
<figure class="table">
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Antiviral &nbsp;
                </td>
                <td>
                    EGFR &nbsp;
                </td>
                <td>
                    Prophylaxis dose &nbsp;
                </td>
            </tr>
            <tr>
                <td rowspan="6">
                    Valganciclovir &nbsp;
                </td>
                <td>
                    &gt; 60
                </td>
                <td>
                    900mg po daily
                </td>
            </tr>
            <tr>
                <td>
                    40-59
                </td>
                <td>
                    450mg po daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    25-39
                </td>
                <td>
                    450mg po every 2 days &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    10-24
                </td>
                <td>
                    450mg twice weekly
                </td>
            </tr>
            <tr>
                <td>
                    &lt; 10 ( HD) &nbsp;
                </td>
                <td>
                    450 mg twice weekly post HD &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    &lt; 10 ( SLED)
                </td>
                <td>
                    Don’t use &nbsp;
                </td>
            </tr>
            <tr>
                <td rowspan="6">
                    Ganciclovir &nbsp;
                </td>
                <td>
                    &gt;70
                </td>
                <td>
                    5mmg/kg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    50-69
                </td>
                <td>
                    2.5mg/kg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    25-49
                </td>
                <td>
                    1.25mg/kg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    10-24
                </td>
                <td>
                    0.625mg/kg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    &lt; 10 ( HD)
                </td>
                <td>
                    0.625 mg/kg post-HD only on HD days
                </td>
            </tr>
            <tr>
                <td>
                    &lt; 10 ( SLED)&nbsp;
                </td>
                <td>
                    .5 mg/kg q24h give post‐SLED&nbsp;
                </td>
            </tr>
        </tbody>
    </table>
</figure>
<p>
    <strong>Acyclovir:</strong>
</p>
<ul>
    <li data-list-item-id="ed3641f9028181171db162868711a37db">
         Indicated for patients not requiring CMV prophylaxis.
    </li>
    <li data-list-item-id="e59f2771c8c5abe1b39636223e83f6cc0">
         Dose: &nbsp;
        <ul>
            <li data-list-item-id="e1135fd35015388f7f283eb5a9fe56657">
                 400 mg PO BID × 1 month
            </li>
            <li data-list-item-id="e5ae709aa3658f38e12356125a0b1f4ba">
                 Renal-adjust per EGFR &nbsp;
            </li>
        </ul>
    </li>
</ul>
<figure class="table">
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Antiviral &nbsp;
                </td>
                <td>
                    EGFR &nbsp;
                </td>
                <td>
                    Prophylaxis dose &nbsp;
                </td>
            </tr>
            <tr>
                <td rowspan="5">
                    Acyclovir &nbsp;
                </td>
                <td>
                    &gt;50
                </td>
                <td>
                    400mg po bid &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    25-49 &nbsp;
                </td>
                <td>
                    400mg po bid
                </td>
            </tr>
            <tr>
                <td>
                    10-24
                </td>
                <td>
                    200mg po bid
                </td>
            </tr>
            <tr>
                <td>
                    &lt;10 ( HD) &nbsp;
                </td>
                <td>
                    200mg 3 times per week post-HD &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    &lt;10 ( SLED)&nbsp;
                </td>
                <td>
                    IV acyclovir 5mg/kg q24hrs Post-SLED.&nbsp;
                </td>
            </tr>
        </tbody>
    </table>
</figure>
<p>
    <strong>Lamivudine / Tenofovir (TDF) / Entecavir</strong>
</p>
<ul>
    <li data-list-item-id="ed492c4874b98c712d71ff5a4e55057a3">
         Indicated for the following:
        <ul>
            <li data-list-item-id="e8f5fae839081da461b4b5f2c1b45b99e">
                 HBV cirrhosis patients
            </li>
            <li data-list-item-id="ebd3d36fdccc19f2fd2a0e765a512f670">
                 Recipients with HBcAb+
            </li>
            <li data-list-item-id="eeb50643f3615cac569f87d1a009b41b1">
                 HBV naïve receiving HBcAb+ graft
            </li>
            <li data-list-item-id="ed5dbed99a7ca06d8caf8088e4bbfe5e9">
                 Any donor with HBsAg+
            </li>
        </ul>
    </li>
    <li data-list-item-id="ea3265eee7894f8dddf932ddc7633097e">
         Dose:
        <ul>
            <li data-list-item-id="ed5291465e732240c4480082193a66ff7">
                 Lamivudine: 100 mg PO daily (renal-adjust).
            </li>
            <li data-list-item-id="e33fefb87818d0e4fe3220be420aa2aef">
                 TDF: 300 mg PO daily (renal-adjust).
            </li>
            <li data-list-item-id="e4892bfecaeec5db95baa914c24a831c7">
                 Entecavir: 0.5 mg PO daily (renal-adjust).&nbsp;
            </li>
        </ul>
    </li>
</ul>
<figure class="table">
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Antiviral &nbsp;
                </td>
                <td>
                    EGFR &nbsp;
                </td>
                <td>
                    Prophylaxis dose &nbsp;
                </td>
            </tr>
            <tr>
                <td rowspan="5">
                    Lamivudine &nbsp;&nbsp;
                </td>
                <td>
                    &gt; 50
                </td>
                <td>
                    100mg &nbsp;po daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    30 – 49
                </td>
                <td>
                    1st dose 100mg then 50mg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    15 – 29
                </td>
                <td>
                    1st dose 100mg then 25mg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    5 – 14
                </td>
                <td>
                    1st dose 35mg then 15mg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    &lt; 5&nbsp;
                </td>
                <td>
                    1st dose 35mg then 10mg daily &nbsp;
                </td>
            </tr>
            <tr>
                <td rowspan="4">
                    TDF&nbsp;
                </td>
                <td>
                    &gt; 50
                </td>
                <td>
                    300mg po daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    30 – 49
                </td>
                <td>
                    300mg po every 48hrs &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    10 – 29
                </td>
                <td>
                    300mg po every 72hrs
                </td>
            </tr>
            <tr>
                <td>
                    &lt; 10 &nbsp;
                </td>
                <td>
                    Don’t Use.&nbsp;
                </td>
            </tr>
            <tr>
                <td rowspan="4">
                    Entecavir &nbsp;
                </td>
                <td>
                    &gt; 50
                </td>
                <td>
                    0.5mg po daily &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    30 – 49
                </td>
                <td>
                    0.5mg po every 48 hrs &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    10 – 29
                </td>
                <td>
                    0.5mg po every 72 hrs
                </td>
            </tr>
            <tr>
                <td>
                    &lt; 10 ( HD or SLED) &nbsp;
                </td>
                <td>
                    0.5mg po every 7 days &nbsp;
                </td>
            </tr>
        </tbody>
    </table>
</figure>
<p>
    <strong>HBIG</strong>
</p>
<ul>
    <li data-list-item-id="e4b89f51002577ce9648dbe0792749a5a">
         Indicated for the following:
        <ul>
            <li data-list-item-id="e1eb58258b12925b97bf9f29639789215">
                 HBV DNA &gt;1000 pre-LT.
            </li>
            <li data-list-item-id="e0544f1355f1e550dcaf4a9488acb9108">
                 Unknown HBV DNA pre-LT (until results).
            </li>
            <li data-list-item-id="e29ef8d1a5ed8d9979b14d0b1f763c681">
                 HBV with HDV co-infection
            </li>
        </ul>
    </li>
    <li data-list-item-id="e8f045a958365d1fa7152182f247f2d55">
         Dose
        <ul>
            <li data-list-item-id="e6ee26f8b6c1da0173b1f4b07aa249f29">
                 10 mL IV during anhepatic phase, then daily × 7 days, weekly × 4 weeks, monthly × 1 year
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>Epclusa / Mavyret</strong>
</p>
<ul>
    <li data-list-item-id="e75c6821d4698c8f6a4229f496b18e4df">
         Indicated for the following: Untreated HCV pre-LT, HCV-positive donor graft recipients.
    </li>
    <li data-list-item-id="eb10989439244c51abd0fef7346f12362">
         Dose:
        <ul>
            <li data-list-item-id="e3bf395c307e736bef1adb5ed46ccb70d">
                 Epclusa (sofosbuvir 400 mg + velpatasvir 100 mg) × 12 weeks.
            </li>
            <li data-list-item-id="e5f0603f4ac21f2924aefe66d0c957f79">
                 Mavyret (glecaprevir 300 mg + pibrentasvir 120 mg) with meals × 8 weeks.
            </li>
            <li data-list-item-id="ea9175c6b687d2b1e7eecda21d8d34649">
                 Typically started at 3 months post-LT&nbsp;
            </li>
        </ul>
    </li>
</ul>